Edesa Biotech, INC DEF 14A proxy statements
Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.
NASDAQ
Edesa Biotech, Inc. has issued its proxy statement detailing the agenda for its 2026 Annual General and Special Meeting of Shareholders, including director elections and equity plan amendments.
NASDAQ
Edesa Biotech, Inc. has filed a definitive proxy statement with the Securities and Exchange Commission pursuant to Section 14(a) of the Securities Exchange Act of 1934.
NASDAQ
Edesa Biotech is asking shareholders to approve an amendment to its 2019 Equity Incentive Compensation Plan to increase the number of shares available for issuance, remove fungible share pool provisions, and increase the number of shares issuable as incentive stock options.
NASDAQ
Edesa Biotech, Inc. has filed a definitive proxy statement with the Securities and Exchange Commission.
NASDAQ
Edesa Biotech's upcoming annual meeting on May 30, 2024, will address the election of directors, executive compensation, an equity incentive plan amendment, and the appointment of auditors.